Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-10-03 am EDT
216.60 SEK   +0.46%
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractory Diffuse Large B-cell Lymphoma
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sobi Sees Revenue Growth at Higher End of Guidance on Expanded Pipeline, Market Presence

07/19/2022 | 02:37am EDT


© MT Newswires 2022
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
09/30Sobi - New number of shares and votes in Swedish Orphan Biovitrum AB
AQ
09/30New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
AQ
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractor..
MT
09/16Swedish Orphan Biovitrum, ADC Therapeutics Win Recommendation For Lymphoma Medication
MT
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
CI
09/16ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Autho..
DJ
09/16EU regulator backs wider use of AstraZeneca COVID therapy
RE
08/30FDA grants priority review to efanesoctocog alfa for people with haemophilia A
AQ
08/30Sanofi and Sobi Announce US Food and Drug Administration Accept Priority Review the Bio..
CI
07/21DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Pegcetacoplan For US$..
MT
More news
Financials
Sales 2022 18 137 M 1 649 M 1 649 M
Net income 2022 2 344 M 213 M 213 M
Net Debt 2022 6 940 M 631 M 631 M
P/E ratio 2022 27,4x
Yield 2022 -
Capitalization 64 112 M 5 828 M 5 828 M
EV / Sales 2022 3,92x
EV / Sales 2023 3,48x
Nbr of Employees 1 554
Free-Float 57,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 216,60 SEK
Average target price 255,00 SEK
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesström Head-Technical Operations
Sector and Competitors